Abpro Holdings, Inc.

Abpro Holdings, Inc., trading on Nasdaq under the ticker ACAB, is a clinical-stage biopharmaceutical company focused on the discovery and development of bispecific antibody-based therapeutics. The company entered the public markets through a SPAC business combination and filed a Form 10-Q with the Securities and Exchange Commission on December 15, 2023, reflecting its third-quarter financial position as a post-combination public entity. Operating in the biotechnology and life sciences sector, Abpro maintains a pipeline targeting oncology and immunology indications. To access full filing histories, deal timelines, and real-time SPAC analytics on Abpro Holdings and thousands of other transactions, sign up for complete data on SpacDesk.